No title
Importance: Blood-based biomarkers (BBM) provide minimally invasive, scalable, lower-cost tools for identifying neurodegenerative diseases, but prospective data on their clinical validity in memory clinic settings are limited. Objective: To evaluate how a tailored plasma BBM panel (phosphorylated tau 181 [pTau181], glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]) during
